These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 15154647)

  • 1. p53 analysis in gallbladder cancer: comparison of gene analysis versus immunohistochemistry.
    Puhalla H; Kandioler D; Ludwig C; Filipits M; Wrba F; Laengle F; Jakesz R; Gruenberger T
    Anticancer Res; 2004; 24(2C):1201-6. PubMed ID: 15154647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer.
    Dong M; Nio Y; Yamasawa K; Toga T; Yue L; Harada T
    J Surg Oncol; 2003 Feb; 82(2):111-20. PubMed ID: 12561067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The predictive value of p53 and p33(ING1b) in patients with Dukes'C colorectal cancer.
    Ahmed IA; Kelly SB; Anderson JJ; Angus B; Challen C; Lunec J
    Colorectal Dis; 2008 May; 10(4):344-51. PubMed ID: 17949449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [P53 gene mutation in gallbladder cancer].
    Roa I; Melo A; Roa J; Araya J; Villaseca M; de Aretxabala X
    Rev Med Chil; 2000 Mar; 128(3):251-8. PubMed ID: 10962865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Staining patterns of p53 immunohistochemistry and their biological significance in colorectal cancer.
    Kaserer K; Schmaus J; Bethge U; Migschitz B; Fasching S; Walch A; Herbst F; Teleky B; Wrba F
    J Pathol; 2000 Mar; 190(4):450-6. PubMed ID: 10699994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P53 gene mutation spectrum and the relationship between gene mutation and protein levels in pterygium.
    Tsai YY; Cheng YW; Lee H; Tsai FJ; Tseng SH; Chang KC
    Mol Vis; 2005 Jan; 11():50-5. PubMed ID: 15682042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer.
    Yamasawa K; Nio Y; Dong M; Yamaguchi K; Itakura M
    Clin Cancer Res; 2002 Aug; 8(8):2563-9. PubMed ID: 12171884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin.
    Ichikawa W; Ooyama A; Toda E; Sugimoto Y; Oka T; Takahashi T; Shimizu M; Sasaki Y; Hirayama R
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):794-801. PubMed ID: 16528528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer.
    Kandioler D; Stamatis G; Eberhardt W; Kappel S; Zöchbauer-Müller S; Kührer I; Mittlböck M; Zwrtek R; Aigner C; Bichler C; Tichy V; Hudec M; Bachleitner T; End A; Müller MR; Roth E; Klepetko W
    J Thorac Cardiovasc Surg; 2008 May; 135(5):1036-41. PubMed ID: 18455581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive effect of p53 and p21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus.
    Heeren PA; Kloppenberg FW; Hollema H; Mulder NH; Nap RE; Plukker JT
    Anticancer Res; 2004; 24(4):2579-83. PubMed ID: 15330218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.
    Gadducci A; Di Cristofano C; Zavaglia M; Giusti L; Menicagli M; Cosio S; Naccarato AG; Genazzani AR; Bevilacqua G; Cavazzana AO
    Anticancer Res; 2006; 26(1B):687-93. PubMed ID: 16739339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 gene mutation and p53 protein overexpression in a patient with simultaneous double cancer of the gallbladder and bile duct associated with pancreaticobiliary maljunction.
    Kasuya K; Nagakawa Y; Matsudo T; Ozawa T; Tsuchida A; Aoki T; Itoi T; Itokawa F
    J Hepatobiliary Pancreat Surg; 2009; 16(3):376-81. PubMed ID: 19183832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The p53 gene in soft tissue sarcomas: prognostic value of DNA sequencing versus immunohistochemistry.
    Taubert H; Würl P; Bache M; Meye A; Berger D; Holzhausen HJ; Hinze R; Schmidt H; Rath FW
    Anticancer Res; 1998; 18(1A):183-7. PubMed ID: 9568075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accumulation of p53 protein as an indicator for p53 gene mutation in breast cancer. Occurrence of false-positives and false-negatives.
    Lohmann D; Ruhri C; Schmitt M; Graeff H; Höfler H
    Diagn Mol Pathol; 1993 Mar; 2(1):36-41. PubMed ID: 8287224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
    Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
    Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY.
    Watanabe J; Nishiyama H; Okubo K; Takahashi T; Toda Y; Habuchi T; Kakehi Y; Tada M; Ogawa O
    Urology; 2004 May; 63(5):989-93. PubMed ID: 15135005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High prevalence of p53 exon 4 mutations in soft tissue sarcoma.
    Das P; Kotilingam D; Korchin B; Liu J; Yu D; Lazar AJ; Pollock RE; Lev D
    Cancer; 2007 Jun; 109(11):2323-33. PubMed ID: 17429838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor progression through epigenetic gene silencing of O(6)-methylguanine-DNA methyltransferase in human biliary tract cancers.
    Koga Y; Kitajima Y; Miyoshi A; Sato K; Kitahara K; Soejima H; Miyazaki K
    Ann Surg Oncol; 2005 May; 12(5):354-63. PubMed ID: 15915369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of response to chemo-radiotherapy and radiotherapy for esophageal squamous cell carcinoma.
    Miyazaki T; Kato H; Faried A; Sohda M; Nakajima M; Fukai Y; Masuda N; Manda R; Fukuchi M; Ojima H; Tsukada K; Kuwano H
    Anticancer Res; 2005; 25(4):2749-55. PubMed ID: 16080521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.